Application No.: 10/664,600 2 Docket No.: 60636(50551)

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions of claims in the application.

1. (Currently amended) A compound of the following formula:

wherein

T is a transportophore,

L is a bond or a linker having a molecular weight up to 240 dalton,

C is a non-antibiotic therapeutic agent, and

m is 1, 2, 3, 4, 5, 6, 7, or 8,

in which the transportophore has an immune selectivity ratio of at least 2, the transportophore is covalently bonded to the non-antibiotic therapeutic agent via the bond or the linker, the transportophore is an amphiphilic molecule having a pKa value of 6.5 to 9.5, and the compound has an immune selectivity ratio of at least 2.

- 2, (Cancelled)
- 3. (original) The compound of claim 1, wherein the transportophore is a cyclic or heterocyclic molecule.
- 4. (original) The compound of claim 3, wherein the cyclic or heterocyclic molecule has an attached sugar.
- 5. (Currently amended) The compound of claim 3, wherein the cyclic or herterocyclic heterocyclic molecule is a macrolactone or macroether.
- 6. (original) The compound of claim 5, wherein the macrolactone or macroether has an attached sugar.

3

Docket No.: 60636(50551)

- 7. (Currently amended) The compound of claim 3, wherein the cyclic or herterocyclic heterocyclic molecule is a macrolide or ketolide having an amino sugar.
- 8. (Currently amended) The compound of claim 7, wherein the cyclic or herterocyclic heterocyclic molecule is a macrolide having mono-, di-, or tri-basic groups.
 - 9. (original) The compound of claim 1, wherein the compound is

$$R^{5}O$$
 OR^{6}
 R^{2}
 $N-R^{1}$
 OR^{3}

wherein

 $X = N(R^7)-CH_2$

 $CII_2-N(R^7)$

C(=O)

 $C(=NOR^8)$

CH(OR9)

CH(NR¹⁰R¹¹)

 $C(=NR^{12})$

OC(=O)

```
Docket No.: 60636(50551)
                                                        4
Application No.: 10/664,600
        C(=0)0
        independently linker
Y =
Z=
        C(=O)-
        CH(R<sup>16</sup>)
R^1 = H
        CH_3
        (C2-C10)alkyl
        (C<sub>1</sub>-C<sub>10</sub>)alkenyl
        (C<sub>1</sub>-C<sub>10</sub>)alkynyl
         (C_1-C_8)[(C_1-C_4)alkoxy]alkyl
         (C_1-C_8)[(C_1-C_4)alkoxy]alkenyl
        (C_6-C_{10})aryl-(C_1-C_5)alkyl
         (C2-C9)heteroaryl-(C1-C5)alkyl
         (C<sub>1</sub>-C<sub>4</sub>)alkyliden-NR<sup>18</sup>R<sup>19</sup>
         Y-R13
         C(=0)-Y-R^{15}
         C(=O)-R^{15}
R^2 = H
         (1',2'-cis)-OH
         (1',2'-trans)-OH
         (1',2'-cis)-OR<sup>15</sup>
         (1',2'-trans)-OR<sup>15</sup>
         (1',2'-cis)-SH
         (1',2'-cis)-S-Y-R<sup>13</sup>
or the R1 and R2 bearing atoms are connected via a -OC(=O)CHR16- element
R^3 = H
         C(=0)-Y-R^{15}
         C(~O)-R15
R^4 = H
```

Application No.: 10/664,600 5 Docket No.: 60636(50551)

```
C(=O)-Y-R^{15}
         C(=O)-R^{15}
R^5 = H
or R<sup>4</sup>, R<sup>5</sup> are connected by Z
R^6 = H
         CH_3
R^7 = H
         CII<sub>3</sub>
          Y-R<sup>13</sup>
         C(=O)-Y-R^{15}
         C(=O)-R^{15}
R^8 = H
          Y-R13
          R13
          C(=0)-R^{17}
          (C1-C10)alkyl
          (C<sub>1</sub>-C<sub>10</sub>)alkenyl
          (C1-C10)alkynyl
          (C_1-C_8)[(C_1-C_4)alkoxy]alkyl
          (C_1-C_8)[(C_1-C_4)alkoxy]alkenyl
          (C_6-C_{10})aryl-(C_1-C_5)alkyl
          (C2-C9)heteroaryl-(C1-C5)alkyl
          (C<sub>1</sub>-C<sub>4</sub>)alkyliden-NR<sup>18</sup>R<sup>19</sup>
```

wherein alkyl, alkenyl, alkynyl, aryl, and heteroaryl groups are optionally substituted by one to five substituents selected independently from halogen, (C_1-C_4) alkyl, (C_1-C_4) alkenyl, (C_1-C_4) alkynyl, (C_3-C_7) cycloalkyl, (C_1-C_6) heterocycloalkyl, (C_6-C_{10}) aryl, (C_1-C_9) heteroaryl, (C_1-C_4) alkoxy, hydroxy, nitro, cyano, azido, mercapto, -NR¹⁸R¹⁹, R¹⁸C(=O)-, R¹⁸C(=O)O-, R¹⁸OC(=O)O-, R¹⁸NHC(=O)-, R¹⁸C(=O)NH-, R¹⁸R¹⁹NC(=O)-and R¹⁸OC(=O)-

Application No.: 10/664,600 6 Docket No.: 60636(50551)

(C₁-C₁₀)alkyl

(C₁-C₁₀)alkenyl

(C₁-C₁₀)alkynyl

 $(C_1-C_8)[(C_1-C_4)alkoxy]alkyl$

 $(C_1-C_8)[(C_1-C_4)alkoxy]alkenyl$

 (C_6-C_{10}) aryl- (C_1-C_5) alkyl

(C2-C9)heteroaryl-(C1-C5)alkyl

wherein alkyl, alkenyl, aryl, and heteroaryl groups are optionally substituted by one to five substituents selected independently from halogen, (C₁-C₄)alkyl, (C₁-C₄)alkcnyl, (C₁-C₄)alkynyl, (C₃-C₇)cycloalkyl, (C₁-C₆)heterocycloalkyl, (C₆-C₁₀)aryl, (C₁-C₉)heteroaryl, (C₁-C₄)alkoxy, hydroxy, nitro, cyano, azido, mercapto, -NR¹⁸R¹⁹, R¹⁸C(=O)-, R¹⁸C(=O)O-, R¹⁸OC(=O)O-, R¹⁸OC(=O)O-, R¹⁸C(=O)NII-, R¹⁸R¹⁹NC(=O)-and R¹⁸OC(=O)-

 R^{10} , R^{11} =

independently H

 (C_1-C_{10}) alkyl

(C₁-C₁₀)alkenyl

(C₁-C₁₀)alkynyl

 $(C_1-C_8)[(C_1-C_4)alkoxy]alkyl$

 $(C_1-C_8)[(C_1-C_4)alkoxy]$ alkenyl

 (C_6-C_{10}) aryl- (C_1-C_5) alkyl

(C2-C9)heteroaryl-(C1-C5)alkyl

(C₁-C₄)alkyliden-NR¹⁸R¹⁹

or $R^{10} = H$ and $R^{11} = -Y - R^{13}$

 $C(=O)-Y-R^{15}$, $-C(=O)-R^{15}$

 $R^{12} = H$

 (C_1-C_{10}) alkyl

(C₁-C₁₀)alkenyl

(C₁-C₁₀)alkynyl

 $(C_1-C_8)[(C_1-C_4)alkoxy]alkyl$

 $(C_1-C_8)[(C_1-C_4)alkoxy]alkenyl$

```
Docket No.: 60636(50551)
Application No.: 10/664,600
                                                               7
         (C_6-C_{10})aryl-(C_1-C_5)alkyl
          (C2-C9)heteroaryl-(C1-C5)alkyl
         (C<sub>1</sub>-C<sub>4</sub>)alkyliden-NR<sup>18</sup>R<sup>19</sup>
          Y-R<sup>13</sup>
R<sup>13</sup>= independently, therapeutic agent
R<sup>15</sup> independently, therapeutic agent
R<sup>16</sup>= independently, H
          CH_3
          (C2-C10)alkyl
          (C1-C10)alkenyl
          (C<sub>1</sub>-C<sub>10</sub>)alkynyl
          (C_1-C_8)[(C_1-C_4)alkoxy]alkyl
          (C<sub>1</sub>-C<sub>8</sub>)[(C<sub>1</sub>-C<sub>4</sub>)alkoxy]alkenyl
          (C_6-C_{10})aryl-(C_1-C_5)alkyl
          (C2-C9)heteroaryl-(C1-C5)alkyl
          (C<sub>1</sub>-C<sub>4</sub>)alkyliden-NR<sup>18</sup>R<sup>19</sup>
          Y-R13,
 R^{17} = O - R^{20}-aryl
           optionally substituted by -X'-Y- therapeutic agent, X'-therapeutic agent wherein X' is S, O,
 or NII
 R^{18}, R^{19}=
                    independently H
           (C_1-C_{10})alkyl
           (C<sub>1</sub>-C<sub>10</sub>)alkenyl
           (C<sub>1</sub>-C<sub>10</sub>)alkynyl
           (C_1-C_8)[(C_1-C_4)alkoxy]alkyl
           (C_1-C_8)[(C_1-C_4)alkoxy]alkenyl
           (C_6-C_{10})aryl-(C_1-C_5)alkyl
           (C2-C9)heteroaryl-(C1-C5)alkyl
 R^{20} = independently,
```

8

Docket No.: 60636(50551)

Halogen

(C₁-C₃)alkyl

 NO_2

CN

OCH₃

 $N(CH_3)_2$

 N_3

SH

 $S(C_1-C_4)$ alkyl,

9

Docket No.: 60636(50551)

10. (original) The compound of claim1, wherein the compound is

$$R^{5}$$
 O
 R^{6}
 R^{2}
 R^{3a}

wherein:

 $N(R^7)$ - CH_2 X = $CH_2-N(R^7)$ C(=O) $C(=NOR^8)$ CH(OR9) CH(NR10R11) $C(=NR^{12})$ OC(=O) C(=O)O independently, linker Y = $\mathbf{Z} =$ C(=O)-CH(R16)- $R^1 =$ H CH₃ (C2-C10)alkyl

10

Docket No.: 60636(50551)

```
(C<sub>1</sub>-C<sub>10</sub>)alkenyl
(C<sub>1</sub>-C<sub>10</sub>)alkynyl
(C_1-C_8)[(C_1-C_4)alkoxy]alkyl
(C_1-C_8)[(C_1-C_4)alkoxy]alkenyl
(C_6-C_{10})aryl-(C_1-C_5)alkyl
(C2-C9)heteroaryl-(C1-C5)alkyl
(C<sub>1</sub>-C<sub>4</sub>)alkyliden-NR<sup>18</sup>R<sup>19</sup>
Y-R13
C(=O)-Y-R^{15}
C(=0)-R^{15}
S(=O)_k(C_1-C_{10})alkyl
S(=O)_k(C_1-C_{10})alkenyl
S(=O)_k(C_1-C_{10})alkynyl
S(=O)_k(C6-C_{10})aryl
S(=O)_k(C_2-C_9)heteroaryl
S(=O)_{k}-Y-R^{15}
S(=0)_k-R^{15}
```

wherein k is 0, 1 or 2 and alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl can optionally be substituted by one to three halogen, cyano, hydroxy, (C_1-C_4) alkyloxy, nitro, (C_1-C_6) alkyl, (C_1-C_6) alkenyl, (C_1-C_6) alkynyl, (C_3-C_7) cycloalkyl, (C_1-C_6) heterocycloalkyl, (C_6-C_{10}) aryl, (C_1-C_9) heteroaryl, $NR^{18}R^{19}$, $R^{18}C(=0)$ -, $R^{18}C(=$

```
R^2 = H

(1',2'-cis)-OH

(1',2'-trans)-OH

(1',2'-cis)-OR^{15}

(1',2'-trans)-OR^{15}

(1',2'-cis)-SH

(1',2'-cis)-S-Y-R^{13}
```

Docket No.: 60636(50551)

```
or the R1 and R2 bearing atoms are connected via a -OC(=0)CHR16- element
R^{3a}, R^{3b} =
                        independently H
                         R^1
                         OH
                         OR^{11}
                        NR^{10}R^{11}
or R^{3a} = R^{3b} = (=0),
                (=NR1)
                O(CH_2)_kO- wherein k is 2 or 3
R^4 = H
        C(=O)-Y-R15
        C(=0)-R^{15}
R^5 = H
or R4, R5 are connected by -Z-
R^6 = H
        CH_3
R^7 = H
        CH_3
        Y-R13
        C(=0)-Y-R15
        C(=O)-R^{15}
R^8 = H
         Y-R<sup>13</sup>
         C(=0)-R^{17}
R^9 =
                 Н
                         (C<sub>1</sub>-C<sub>10</sub>)alkyl
                         (C<sub>1</sub>-C<sub>10</sub>)alkenyl
                         (C1-C10)alkynyl
```

11

 $(C_1-C_8)[(C_1-C_4)alkoxy]alkyl$

Application No.: 10/664,600 12 Docket No.: 60636(50551)

 $(C_1-C_8)[(C_1-C_4)alkoxy]alkenyl$ $(C_6-C_{10})aryl-(C_1-C_5)alkyl$ $(C_2-C_9)heteroaryl-(C_1-C_5)alkyl$ $R^{10}, R^{11}=$ independently H $(C_1-C_{10})alkyl$ $(C_1-C_{10})alkenyl$ $(C_1-C_{10})alkynyl$ $(C_3-C_{10})cycloalkyl$ $(C_3-C_{10})cycloalkyl$ $(C_6-C_{10})aryl$ $(C_6-C_{10})aryl$ $(C_2-C_9)heteroaryl$

wherein alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl are optionally substituted by one to three halogen, cyano, hydroxy, (C_1-C_4) alkyloxy, nitro, (C_1-C_6) alkyl, (C_1-C_6) alkenyl, (C_1-C_6) alkynyl, (C_3-C_7) cycloalkyl, (C_1-C_6) heterocycloalkyl, (C_6-C_{10}) aryl, (C_1-C_9) heteroaryl, $NR^{18}R^{19}$, $R^{18}C(=0)$ -, $R^$

or $R^{10} = H$ and $R^{11} = Y - R^{13}$ $C(=O) - Y - R^{15}$ $C(=O) - R^{15}$ $S(=O)_k(C_1 - C_{10})$ $S(=O)_k(C_1 - C_{10})$ $S(=O)_k(C_1 - C_{10})$ $S(=O)_k(C_0 - C_{10})$ $S(=O)_k(C_0 - C_{10})$ $S(=O)_k(C_0 - C_{10})$ $S(=O)_k - Y - R^{15}$ $S(=O)_k - R^{15}$

wherein k is 0, 1 or 2 and alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl can be substituted as defined above.

13

Docket No.: 60636(50551)

```
R^{12} = H
          (C_1-C_{10})alkyl
          (C<sub>1</sub>-C<sub>10</sub>)alkenyl
          (C<sub>1</sub>-C<sub>10</sub>)alkynyl
          (C_1-C_8)[(C_1-C_4)alkoxy]alkyl
          (C_1-C_8)[(C_1-C_4)alkoxy]alkenyl
          (C_6-C_{10})aryl-(C_1-C_5)alkyl
          (C2-C9)heteroaryl-(C1-C5)alkyl
          (C<sub>1</sub>-C<sub>4</sub>)alkyliden-NR<sup>18</sup>R<sup>19</sup>
          Y-R13
R<sup>13</sup>= independently, therapeutic agent
R<sup>15</sup>= independently, therapeutic agent
R<sup>16</sup>= independently, H
          CH<sub>3</sub>
          (C2-C10)alkyl
          (C<sub>1</sub>-C<sub>10</sub>)alkenyl
          (C_1-C_{10})alkynyl
          (C_1-C_8)[(C_1-C_4)alkoxy]alkyl
          (C_1-C_8)[(C_1-C_4)alkoxy]alkenyl
          (C_6-C_{10})aryl-(C_1-C_5)alkyl
          (C2-C9)heteroaryl-(C1-C5)alkyl
          (C<sub>1</sub>-C<sub>4</sub>)alkyliden-NR<sup>18</sup>R<sup>19</sup>
          Y-R13
 R^{17} = O - R^{20}-aryl
           optionally substituted by -X'-Y- therapeutic agent, X'- therapeutic agent wherein X' is
 S, O, NH
 R^{18}, R^{19}=
                               independently H
```

(C₁-C₁₀)alkyl (C₁-C₁₀)alkenyl

14

Docket No.: 60636(50551)

 (C_1-C_{10}) alkynyl

 $(C_1\text{-}C_8)[(C_1\text{-}C_4)alkoxy]alkyl$

 $(C_1-C_8)[(C_1-C_4)alkoxy]alkenyl$

 (C_6-C_{10}) aryl- (C_1-C_5) alkyl

 (C_2-C_9) heteroaryl- (C_1-C_5) alkyl

R²⁰ = independently,

Halogen

 (C_1-C_3) alkyl

 NO_2

CN

OCH₃

 $N(CH_3)_2$

 N_3

SH

 $S(C_1-C_4)$ alkyl.

11. (original) The compound of claim 1, wherein the compound is

wherein

$$X = N(R^9)-CH_2$$

 $CH_2-N(R^9)$

C(=O)

15

Docket No.: 60636(50551)

```
C(=NOR^{10})
C(OR^{11})H
CH(NR^{12}R^{13})
C(=NR^{14})
OC(=O)
C(=O)O
Y = independently, linker
<math display="block">R^{1} = OR^{17}
NR^{17}R^{18},
```

or R^1 is connected to the oxygen bearing R^4 or R^5 forming a lactone or is connected to a suitable substituent in R^2 forming a lactone or lactam,

```
R<sup>2</sup> = O-2-cladinosyl ( )

H

X', whercin X'= halogen
azido
nitro
cyano
OR<sup>17</sup>
OR<sup>22</sup>
NR<sup>17</sup>R<sup>18</sup>
SR<sup>17</sup> (C<sub>1</sub>-C<sub>6</sub>)alkyl
(C<sub>1</sub>-C<sub>6</sub>)alkenyl
(C<sub>1</sub>-C<sub>6</sub>)alkynyl
```

Application No.: 10/664,600 16 Docket No.: 60636(50551)

(C3-C10)cycloalkyl

(C₁-C₉)heterocycloalkyl

(C₆-C₁₀)aryl

(C₁-C₉)heteroaryi

wherein alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl groups are optionally substituted by one to five substituents selected independently from halogen, (C₁-C₄)alkyl, (C₁-C₄)alkenyl, (C₁-C₄)alkynyl, (C₃-C₇)cycloalkyl, (C₁-C₆)heterocycloalkyl, (C₆-C₁₀)aryl, (C₁-C₉)heteroaryl, (C₁-C₄)alkoxy, hydroxy, nitro, cyano, azido, mercapto, R²⁰R²¹N-, R²⁰C(=O)-, R²⁰C(=O)-, R²⁰C(=O)-, R²⁰C(=O)-, R²⁰C(=O)-, and R²⁰OC(=O)-, -Y-therapeutic agent or -therapeutic agent,

 $R^{3} = H$ $(C_{1}-C_{6})alkyl$ $(C_{1}-C_{6})alkenyl$ $(C_{1}-C_{6})alkynyl$ $(C_{3}-C_{10})cycloalkyl$ $(C_{1}-C_{9})hctcrocycloalkyl$ $(C_{6}-C_{10})aryl$

 (C_1-C_9) hcteroaryl

wherein alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl groups are optionally substituted by one to five substituents selected independently from halogen, (C_1-C_4) alkyl, (C_1-C_4) alkynyl, (C_3-C_7) cycloalkyl, (C_1-C_6) heterocycloalkyl, (C_6-C_{10}) aryl, (C_1-C_{10}) aryl, (C_1-C_{10}) aryl, (C_1-C_1) aryl, (C_1-C_2) aryl, (C_1-C_1) aryl, (C_1-C_2) aryl

35 U.S.C. 102(b) C₂)heteroaryl, (C₁-C₄)alkoxy, or R²⁰R²¹N-

$$R^{16}$$
 N—

 $R^4 = O-2$ -desosaminyl ()

Application No.: 10/664,600 17 Docket No.: 60636(50551)

 $C(=O)R^{17}$

Y- therapeutic agent

therapeutic agent

S(=O)₂R¹⁷ providing R¹⁷ is not hydrogen

 $C(=O)NR^{17}R^{18}(C_1-C_6)alkyl$

(C₁-C₆)alkenyl

(C1-C6)alkynyl

(C3-C10)cycloalkyl

(C1-C9)heterocycloalkyl

 (C_6-C_{10}) aryl

(C₁-C₉)heteroaryl

wherein alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl groups are optionally substituted by one to five substituents selected independently from halogen, (C₁-C₄)alkyl, (C₁-C₄)alkenyl, (C₁-C₄)alkynyl, (C₃-C₇)cycloalkyl, (C₁-C₆)heterocycloalkyl, (C₆-C₁₀)aryl, (C₁-C₉)heteroaryl, (C₁-C₄)alkoxy, hydroxy, nitro, cyano, azido, mercapto, R²⁰R²¹N-, R²⁰C(=O)-, R²⁰C(=O)-, R²⁰C(=O)-, R²⁰C(=O)NII-, R²⁰R²¹NC(=O)-, and R²⁰OC(=O)O-, -Y-therapeutic agent or -therapeutic agent,

or R^4 is connected to a suitable R^2 containing a N or a O by -C(=O), S(=O)_n wherein n = 1 or 2, -C $R^{20}R^{17}$ -, CR²⁰(-Y- therapeutic agent)-, -CR²⁰(- therapeutic agent)- forming in dependence of R^2 a 6 or 7-membered ring,

$$R^5 = R^{20}$$
 $C(=O)R^{20}$

or R^4 , R^5 are connected by C(=O), $S(=O)_n$ wherein n=1 or 2, $-CR^{20}R^{17}$ -, $CR^{20}(-Y$ - therapeutic agent)-, $-CR^{20}(-X)$ - therapeutic agent)-

 $R^{6}, R^{8} =$

independently H

(C₁-C₆)alkyl

(C₁-C₆)alkenyl

(C₁-C₆)alkynyl

(C₃-C₁₀)cycloalkyl

Application No.: 10/664,600 18 Docket No.: 60636(50551)

(C1-C9)heterocycloalkyl

 (C_6-C_{10}) aryl

(C₁-C₉)heteroaryl

wherein alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl groups are optionally substituted by one to five substituents selected independently from halogen, (C₁-C₄)alkyl, (C₁-C₄)alkenyl, (C₁-C₄)alkynyl, (C₃-C₇)cycloalkyl, (C₁-C₆)heterocycloalkyl, (C₆-C₁₀)aryl, (C₁-C₉)heteroaryl, (C₁-C₄)alkoxy, hydroxy, nitro, cyano, azido, mercapto, R²⁰R²¹N-, R²⁰C(=O)-, R²⁰C(=O)-, R²⁰C(=O)-, R²⁰C(=O)-, R²⁰C(=O)NH-, R²⁰R²¹NC(=O)-, and R²⁰OC(=O)-, -Y-therapeutic agent or -therapeutic agent,
or R⁶, R⁸ = independently -C(=O)R¹⁷, -Y- therapeutic agent, - therapeutic agent, -S(=O)2R¹⁷

or R^6 , R^8 = independently -C(=O) R^{17} , -Y- therapeutic agent, - therapeutic agent, -S(=O) $2R^{17}$ providing R^{17} is not hydrogen, -C(=O) $NR^{17}R^{18}$,

 $R^7 = H$

(C₁-C₆)alkyl

(C₁-C₆)alkenyl

(C₁-C₆)alkynyl

(C₃-C₁₀)cycloalkyl

(C1-C9)heterocycloalkyl

(C₆-C₁₀)aryl

(C₁-C₉)heteroaryl

wherein alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl groups are optionally substituted by one to five substituents selected independently from halogen, (C₁-C₄)alkyl, (C₁-C₄)alkenyl, (C₁-C₄)alkynyl, (C₃-C₇)cycloalkyl, (C₁-C₆)heterocycloalkyl, (C₆-C₁₀)aryl, (C₁-C₉)heteroaryl, (C₁-C₄)alkoxy, hydroxy, nitro, cyano, azido, mercapto, R²⁰R²¹N-, R²⁰C(=O)-, R²⁰C(=O)-, R²⁰C(=O)-, R²⁰C(=O)-, R²⁰C(=O)NH-, R²⁰R²¹NC(=O)-, and R²⁰OC(=O)O-, -Y-therapeutic agent or -therapeutic agent,

or two of each R^6 , R^7 , R^8 are connected by -C(=0), $S(=0)_n$ wherein n=1 or 2, $-CR^{20}R^{17}$ -, $CR^{20}(-1)_n$ wherein n=1 or 2, $-CR^{20}R^{17}$ -, $-CR^{20}(-1)_n$ wherein $-CR^{20}R^{17}$ -, $-CR^$

 $R^9 = H$ CII_3

Application No.: 10/664,600 19 Docket No.: 60636(50551)

Y-therapeutic agent

therapeutic agent

(C₁-C₆)alkyl

(C₁-C₆)alkenyl

(C₁-C₆)alkynyl,

wherein alkyl, alkenyl, alkynyl groups are optionally substituted by one to five substituents selected independently from halogen, (C_1-C_4) alkyl, (C_1-C_4) alkenyl, (C_1-C_4) alkynyl, (C_3-C_7) cycloalkyl, (C_1-C_6) heterocycloalkyl, (C_6-C_{10}) aryl, (C_1-C_9) heteroaryl, (C_1-C_4) alkoxy, hydroxy, nitro, cyano, azido, mercapto, $R^{20}R^{21}N$ -, $R^{20}C(=0)$ -, $R^{20}C(=0)$ 0-, $R^{20}OC(=0)$ -, $R^{20}NHC(=0)$ -, $R^{20}C(=0)$ NH-, $R^{20}R^{21}NC(=0)$ -, and $R^{20}OC(=0)$ 0-,

-Y- therapeutic agent or -therapeutic agent,

$$R^{10} = C(=0) - aryl$$

therapeutic agent,

H

(C₁-C₆)alkyl

(C₁-C₆)alkenyl

(C₁-C₆)alkynyl,

wherein alkyl, alkenyl, alkynyl groups are optionally substituted by one to five substituents selected independently from halogen, (C_1-C_4) alkyl, (C_1-C_4) alkenyl, (C_1-C_4) alkynyl, (C_3-C_7) cycloalkyl, (C_1-C_6) heterocycloalkyl, (C_6-C_{10}) aryl, (C_1-C_9) heteroaryl, (C_1-C_4) alkoxy, hydroxy, nitro, cyano, azido, mercapto, $R^{20}R^{21}N$ -, $R^{20}C(=0)$ -, $R^{20}C(=0)$ 0-, $R^{20}OC(=0)$ -, $R^{20}NHC(=0)$ -, $R^{20}C(=0)NH$ -, $R^{20}R^{21}NC(=0)$ -, and $R^{20}OC(=0)$ 0-,

-Y-therapeutic agent or - therapeutic agent

$$R^{11} = H$$

 (C_1-C_6) alkyl

(C₁-C₆)alkenyl

(C₁-C₆)alkynyl,

wherein alkyl, alkenyl, alkynyl groups are optionally substituted by one to five substituents selected independently from halogen, (C₁-C₄)alkyl, (C₁-C₄)alkenyl, (C₁-C₄)alkynyl, (C₃-C₇)cycloalkyl, (C₁-C₄)alkynyl, (C₃-C₇)cycloalkyl, (C₁-C₄)alkynyl, (C₁-C₄)

20

Docket No.: 60636(50551)

C₆)heterocycloalkyl, (C₆-C₁₀)aryl, (C₁-C₉)heteroaryl, (C₁-C₄)alkoxy, hydroxy, nitro, cyano, azido, mercapto, $R^{20}R^{21}N$ -, $R^{20}C(=O)$ -, $R^{20}C(=O)$ -, $R^{20}OC(=O)$ -, $R^{20}NHC(=O)$ -, $R^{20}C(=O)NH$ -, $R^{20}R^{21}NC(=O)$ -, $R^{20}OC(=O)$ -, -Y- therapeutic agent or -therapeutic agent, or R^{11} = -Y- therapeutic agent, - therapeutic agent, -C(=O) R^{17}

 R^{12} , $R^{13} =$

independently H

(C₁-C₆)alkyl

(C₁-C₆)alkenyl

(C1-C6)alkynyl

(C₃-C₁₀)cycloalkyl

(C1-C9)heterocycloalkyl

(C₆-C₁₀)aryl

(C1-C9)heteroaryl,

wherein alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl groups are optionally substituted by one to five substituents selected independently from halogen, (C_1-C_4) alkyl, (C_1-C_4) alkynyl, (C_3-C_7) cycloalkyl, (C_1-C_6) heterocycloalkyl, (C_6-C_{10}) aryl, (C_1-C_9) heteroaryl, (C_1-C_4) alkoxy, hydroxy, nitro, cyano, azido, mercapto, $R^{20}R^{21}N$ -, $R^{20}C(=O)$ -, $R^{20}C$

or R^{12} , R^{13} = independently -C(=O) R^{17} , -Y- therapeutic agent, - therapeutic agent, -S(=O)₂ R^{17} providing R^{17} is not hydrogen, -C(=O) $NR^{17}R^{18}$

R¹⁴ = therapcutic agent

Н

(C₁-C₆)alkyl

(C₁-C₆)alkenyl

(C₁-C₆)alkynyl

(C₃-C₁₀)cycloalkyl

(C1-C9)heterocycloalkyl

 (C_6-C_{10}) aryl

(C₁-C₉)heteroaryl

21

Docket No.: 60636(50551)

wherein alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl groups are optionally substituted by one to five substituents selected independently from halogen, (C₁-C₄)alkyl, (C₁-C₄)alkynyl, (C₃-C₇)cycloalkyl, (C₁-C₆)heterocycloalkyl, (C₆-C₁₀)aryl, (C₁-C₉)heteroaryl, (C₁-C₄)alkoxy, hydroxy, nitro, cyano, azido, mercapto, R²⁰R²¹N-, R²⁰C(=O)-, R²⁰C(=O)-, R²⁰OC(=O)-, R²⁰OC(=O)-, R²⁰OC(=O)-, R²⁰OC(=O)-, -Y-therapeutic agent or –therapeutic agent,

 $R^{15} = H$

 $C(=0)R^{17}$

Y- therapeutic agent,

therapeutic agent,

 $S(=O)_2R^{17}$ providing R^{17} is not hydrogen

 $C(=0)NR^{17}R^{18}$

(C1-C6)alkyl

(C₁-C₆)alkenyl

(C₁-C₆)alkynyl

(C3-C10)cycloalkyl

(C₁-C₉)heterocycloalkyl

 (C_6-C_{10}) aryl

(C1-C9)heteroaryl,

wherein alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl groups are optionally substituted by one to five substituents selected independently from halogen, (C₁-C₄)alkyl, (C₁-C₄)alkenyl, (C₁-C₄)alkynyl, (C₃-C₇)cycloalkyl, (C₁-C₆)heterocycloalkyl, (C₆-C₁₀)aryl, (C₁-C₉)heteroaryl, (C₁-C₄)alkoxy, hydroxy, nitro, cyano, azido, mercapto, R²⁰R²¹N-, R²⁰C(=O)-, R²⁰C(=O)-, R²⁰OC(=O)-, R²⁰OC(=O)-, R²⁰C(=O)NH-, R²⁰R²¹NC(=O)-, and R²⁰OC(=O)O-, -Y-therapeutic agent or -therapeutic agent,

 R^{16} = independently, H OR^{17} OR^{22}

R¹⁷, R¹⁸ = independently H

Application No.: 10/664,600 22 Docket No.: 60636(50551)

(C₁-C₆)alkyl

(C₁-C₆)alkenyl

(C₁-C₆)alkynyl

(C3-C10)cycloalkyl

(C₁-C₉)heterocycloalkyl

(C₆-C₁₀)aryl

(C₁-C₂)heteroaryl

wherein alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl groups are optionally substituted by one to five substituents selected independently from halogen, (C_1-C_4) alkyl, (C_1-C_4) alkynyl, (C_3-C_7) cycloalkyl, (C_1-C_6) heterocycloalkyl, (C_6-C_{10}) aryl, (C_1-C_9) heteroaryl, (C_1-C_4) alkoxy, hydroxy, nitro, cyano, azido, mercapto, $R^{20}R^{21}N$ -, $R^{20}C(=0)$ -, and $R^{20}OC(=0)$ -, -Y-therapeutic agent or –therapeutic agent, or provided that connected to a nitrogen, R^{17} , R^{18} may form a cyclic structure of 4 to 7 members (including the nitrogen). R^{17} and R^{18} then can represent a fragment from the type of $-[C(AB)]_m$ - E_n - $[C(DE)]_o$ - Ψ_p - $[C(GI)]_q$ wherein m, n, o, p and q independently are 0, 1, 2, 3, 4, 5, or 6, E and E0 independently are -O-, -S-, -NK- and A, B, D, E, G, J, and K independently are hydrogen, E1 alkyl, E1, E2, E3, alkynyl, E3, and E3, and E3, and E4, alkyl, E4, alkenyl, E5, and E6, and E8, and E8, and E9, and an arrow are open are op

 $R^{20}C(=0)O-$, $R^{20}OC(=0)-$, $R^{20}NHC(=0)-$, $R^{20}C(=0)NII-$, $R^{20}R^{21}NC(=0)-$, and $R^{20}OC(=0)O-$

 R^{20} , R^{21} = independently H

(C₁-C₆)alkyl

 R^{22} = independently, C(=0) R^{17}

Y- therapeutic agent

therapeutic agent,

S(=O)₂R¹⁷ providing R¹⁷ is not hydrogen, -C(=O)NR¹⁷R¹⁸.

23

Docket No.: 60636(50551)

12. (original) The compound of claim 1, wherein the compound is

$$\begin{pmatrix} A \\ M \end{pmatrix}_{m} \begin{pmatrix} A \\ M \end{pmatrix}_{m}$$

wherein:

m = independently, 0, 1, 2, 3

n = 0 - 7

X = independently, O

S

Se

 NR^1

 PR^1

with the proviso, that at least one $X = -NR^1$ -

 $A = independently, CH_2$

CHR²

 CR^2R^3

C(=O)

with the proviso, that at least one $X = -NR^{1}$ is not an amide

R¹ = independently, H

(C₁-C₁₀)alkyl, optionally substituted by fluoro, cyano, R⁴, R⁴O₂C, R⁴C(=O)NH and

 $R^4S(=0)_k$ wherein k is 0,1 or 2

 $R^4C(=O)$, $R^4S(=O)_k$ wherein k is 0, 1 or 2

 R^2 , R^3 = independently NH_2

NHR¹

Application No.: 10/664,600 24 Docket No.: 60636(50551)

$$\label{eq:NR} \begin{split} NR^1R^5 \\ OH, \\ OR^4 \\ R^4C(=O) & (C_1-C_6)alkyl \\ (C_2-C_{12})alkenyl \\ (C_2-C_{12})alkynyl \\ (C_3-C_{10})cycloalkyl(C_1-C_6)alkyl \\ (C_2-C_9)heterocycloalkyl(C_1-C_6)alkyl \end{split}$$

 (C_6-C_{10}) aryl (C_1-C_6) alkyl

 (C_2-C_9) heteroaryl (C_1-C_6) alkyl,

wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl groups are optionally substituted by one to three halo, (C_1-C_4) alkoxy, hydroxy, nitro, cyano, $-C(=O)-OR^8$, $-C(=O)N(H)R^8$, (C_6-C_{10}) aryl, (C_2-C_9) heteroaryl, $N*R^5R^6R^7$ wherein * is no or a positive charge, one or two of R^2 , R^3 can be a directly coupled therapeutic agent,

R⁴ = independently,

 NH_2

NHR⁹

NR9R5

OH

OR9

(C₁-C₆)alkyl

(C2-C12)alkenyl

(C₂-C₁₂)alkynyl

(C₃-C₁₀)cycloalkyl(C₁-C₆)alkyl

(C2-C9)heterocycloalkyl(C1-C6)alkyl

 (C_6-C_{10}) aryl (C_1-C_6) alkyl

 (C_2-C_9) heteroaryl (C_1-C_6) alkyl,

25

Docket No.: 60636(50551)

wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl groups are optionally substituted by one to three halo, (C₁-C₄)alkoxy, hydroxy, nitro, cyano, R⁸, -C(=O)-OR⁸, -C(=O)N(H)R⁸, (C₆-C₁₀)aryl, (C₂-C₉)heteroaryl, N*R⁵R⁶R⁷ wherein * is no or a positive charge, or a therapeutic agent,

 R^5 , R^6 = independently H

(C₁-C₆), optionally substituted by hydroxy

 (C_6-C_{10}) aryl

(C2-C9)heteroaryl

R⁷ = independently,

lone electron pair

CH₃

 C_2H_5

 C_3H_7

CH2-C6H5

R⁸ = independently, therapeutic agent

R⁹ = independently,

(C₁-C₆) alkyl

(C₂-C₁₂)alkenyl

(C2-C12)alkynyl

 (C_3-C_{10}) cycloalkyl (C_1-C_6) alkyl

(C2-C9)heterocycloalkyl(C1-C6)alkyl

(C6-C10)aryl(C1-C6)alkyl or

 (C_2-C_9) heteroaryl (C_1-C_6) alkyl,

wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl groups are optionally substituted by one to three halo, (C₁-C₄)alkoxy, hydroxy, nitro, cyano, R⁸, -C(=O)-OR⁸, -C(=O)N(H)R⁸, (C₆-C₁₀)aryl, (C₂-C₉)heteroaryl, N*R⁵R⁶R⁷ wherein * is no or a positive charge, or a therapeutic agent.

13. (original) The compound of claim 1, wherein the linker is

Application No.: 10/664,600 26 Docket No.: 60636(50551)

(C₁-C₈)alkyl,

(C₁-C₈)alkenyl,

 (C_1-C_8) alkynyl,

(C3-C10)cycloalkyl,

 (C_6-C_{10}) aryl,

(C2-C9)heteroalkyl, or

(C2-C9)heteroaryl,

wherein alkyl-, alkenyl, alkynyl, cycloalkyl, aryl or heteroaryl spacing clements are optionally substituted by (C_1-C_6) alkyl, 1-4 halogens, (C_1-C_4) alkoxy, (C_1-C_4) alkoxycarbonyl, hydroxy, amino, (C_1-C_4) alkylamino, (C_1-C_4) dialkylamino, (C_3-C_{10}) cycloalkyl, (C_1-C_6) alkylcarbonyloxy, (C_1-C_6) alkylcarbonylamido, (C_1-C_4) alkylamidocarbonyl, (C_1-C_4) dialkylamidocarbonyl, nitro, cyano, (C_1-C_4) alkylimino, mercapto or (C_1-C_4) alkylmercapto.

- 14. (original) The compound of claim 1, wherein the non-antibiotic therapeutic agent is an anti-inflammatory agent.
- 15. (original) The compound of claim 1, wherein the non-antibiotic therapeutic agent is an anti-infectious agent.
- 16. (original) The compound of claim 1, wherein the non-antibiotic therapeutic agent is an anti-cancer agent.
- 17. (original) The compound of claim 1, wherein the non-antibiotic therapeutic agent is an allergy-suppressive agent.
- 18. (original) The compound of claim 1, wherein the non-antibiotic therapeutic agent is an immune-suppressant agent.

27

Docket No.: 60636(50551)

- 19. (original) The compound of claim 1, wherein the non-antibiotic therapeutic agent is an agent for treating a hematopoietic disorder.
- 20. (original) The compound of claim 1, wherein the non-antibiotic therapeutic agent is an agent for treating a metabolic disease.
- 21. (original) A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
- 22. (original) A method of treating an inflammatory disorder, comprising administering to a subject in need thereof an effective amount of a compound of claim 1, wherein the non-antibiotic therapeutic agent is an anti-inflammatory agent.
- 23. (original) A method of treating an infectious disease, comprising administering to a subject in need thereof an effective amount of a compound of claim 1, wherein the non-antibiotic therapeutic agent is an anti-infectious agent.
- 24. (original) A method of treating cancer, comprising administering to a subject in need thereof an effective amount of a compound of claim 1, wherein the non-antibiotic therapeutic agent is an anti-cancer agent.
- 25. (original) A method of treating allergy, comprising administering to a subject in need thereof an effective amount of a compound of claim 1, wherein the non-antibiotic therapeutic agent is an allergy-suppressive agent.
- 26. (original) A method of treating an immune disorder, comprising administering to a subject in need thereof an effective amount of a compound of claim 1, wherein the non-antibiotic therapeutic agent is an immune-suppressant agent.